| Literature DB >> 35745266 |
Jesse P Caron1, Margaret Ann Kreher1, Angela M Mickle1, Stanley Wu1, Rene Przkora1,2, Irene M Estores1, Kimberly T Sibille1,2.
Abstract
Dietary behavior can have a consequential and wide-ranging influence on human health. Intermittent fasting, which involves intermittent restriction in energy intake, has been shown to have beneficial cellular, physiological, and system-wide effects in animal and human studies. Despite the potential utility in preventing, slowing, and reversing disease processes, the clinical application of intermittent fasting remains limited. The health benefits associated with the simple implementation of a 12 to 16 h fast suggest a promising role in the treatment of chronic pain. A literature review was completed to characterize the physiologic benefits of intermittent fasting and to relate the evidence to the mechanisms underlying chronic pain. Research on different fasting regimens is outlined and an overview of research demonstrating the benefits of intermittent fasting across diverse health conditions is provided. Data on the physiologic effects of intermittent fasting are summarized. The physiology of different pain states is reviewed and the possible implications for intermittent fasting in the treatment of chronic pain through non-invasive management, prehabilitation, and rehabilitation following injury and invasive procedures are presented. Evidence indicates the potential utility of intermittent fasting in the comprehensive management of chronic pain and warrants further investigation.Entities:
Keywords: chronic pain; intermittent fasting; non-invasive management; prehabilitation; rehabilitation
Mesh:
Year: 2022 PMID: 35745266 PMCID: PMC9228511 DOI: 10.3390/nu14122536
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 6.706
Description of common fasting regimens.
| Fasting Type | Regimen | Description |
|---|---|---|
|
| Complete-alternate-day fasting [ | No energy-containing foods or beverages on fasting days alternating with ad libitum intake on consumption days |
| Modified-alternate day fasting [ | 20–40% of energy requirements consumed on fasting days alternating with ad libitum intake on consumption days | |
| 5:2 [ | Restriction to 25% or less of calorie requirements 2 days per week (consecutive or non-consecutive days) with ad libitum intake the remaining 5 days | |
| Time-restricted feeding | Ad libitum energy intake within a 6–12 h period, no energy-containing foods for the remaining 12–18 h in a 24 h period | |
|
| Prolonged fasting [ | 2 to 21 days of very little or no energy intake (water-only fast) followed by a period of ad libitum intake |
| Fasting-mimicking diet | Low-calorie, low-sugar, low-protein, high-unsaturated fat diet (30–50% of energy requirements) for 4–7 consecutive days with ad libitum eating the rest of the month. |
* Ramadan fasting (no energy consumption from dawn to sunset during the month of Ramadan) may be considered as a form of time-restricted feeding [19].
Definitions, mechanisms, and potential benefits of fasting.
| Pain State | Definition | Relevant Mechanisms | Examples | Potential Benefits of Fasting |
|---|---|---|---|---|
|
| Pain resulting from abnormal stress on muscles, bones, joints, or soft tissue | Mechanical nociceptors triggered by excess pressure or mechanical deformation on a muscle, bone, joint, or soft tissue due to acute or cumulative trauma. May or may not involve tissue damage [ |
Osteoarthritic pain caused by degeneration of articular cartilage Mechanical low back pain due to herniated intervertebral disk MSK injuries including muscle strain, tendinopathy, bone fracture Incision breaking the skin surface |
Reduced fasting insulin, which promotes cartilage degradation [ Promotes weight loss to reduce mechanical stress on joints and improve symptoms of osteoarthritis [ Improved mood and weight loss for increased participation in physical therapy [ |
|
| Persistent or recurrent pain due to inappropriate activation of the inflammatory response | The inflammatory cascade includes release of chemical mediators including cytokines and prostaglandins that sensitize nociceptors [ |
Rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus, and other autoimmune diseases Gout Inflammatory bowel disease Upregulated pain from inflammatory mediators released from adipose tissue in obesity |
Decreased oxidative stress and inflammation, including CRP levels [ Stimulates autophagy [ Reduced adipose tissue, which promotes a systemic inflammatory state that likely contributes to osteoarthritis [ |
|
| Pain resulting from a lesion in the somatosensory pathway |
Damage to the nervi nervorum in ascending pathway results in hypersensitivity of nociception. Associated with neurochemical biomarkers substance P, nerve growth factor, IL-8 [ |
Diabetic neuropathy, lumbar and cervical radiculopathy, traumatic neuralgia Peripheral and central sensitization is thought to contribute to osteoarthritic pain. |
Enhanced synaptic plasticity via increased BDNF [ Increased myelin protein expression resulting in thicker myelin sheath and decreased aberrant Schwann cell proliferation, thus improving peripheral nerve function [ |
|
| Pain resulting from diminished or absent perfusion to tissues | During ischemic injury, metabolites including ATP and lactic acid accumulate, inflammatory cytokines are released, and group III and IV nociceptive afferents are sensitized. Ischemia-reperfusion injury generates free radicals and ROS, and increased microvascular permeability during reperfusion allows inflammatory cell infiltration and release of pro-algesic cytokines including IL-1 and TNF-alpha [ |
Post-surgical ischemia-reperfusion injury Peripheral vascular disease Sickle cell crisis Myocardial infarction Mesenteric ischemia |
Improved recovery following ischemic injury and decreased vascular inflammation [ Attenuated sympathetic vasoconstriction [ Reduced development of atherosclerosis through improved metabolic profile [ |
|
| Pain originating from visceral organs including lower airways, heart, mesentery, and hollow organs of the GI tract | Stimulated by chemical irritants, ischemia, distention, and inflammation. Tissue injury is not required. May be referred to somatically innervated structures corresponding to the spinal level of the affected visceral site [ |
Pain associated with inflammatory bowel disease, constipation, bowel obstruction, irritable bowel syndrome Menstrual pain |
Modulation of gut microbiota, promoting intestinal regeneration and decreasing symptoms of inflammation [ Improves GI motility via increased parasympathetic tone [ |
|
| Disturbance in pain processing in the central nervous system resulting in diffuse or regional hyperalgesia | Elevated underlying levels of pronociceptive neurotransmitters (substance P, glutamate) and reduced levels of neurotransmitters that inhibit pain (serotonin, norepinephrine, dopamine). Implication of the endocannabinoid system, but not the endogenous opioid system (which is augmented in fibromyalgia) [ |
Fibromyalgia Irritable bowel syndrome Tension headache Idiopathic low back pain Chronic pelvic pain Myofascial pain syndrome |
Mood enhancement—specifically, increased feelings of well-being, focus, and euphoria [ Release of norepinephrine, epinephrine, dopamine, and cortisol in the early phase of fasting with corresponding activation of stress resistance mechanisms [ Increased availability of tryptophan and serotonin in the CNS [ Ketosis-induced neurogenesis, neurotrophic factor synthesis, and expression of neurotransmitter receptors [ Improved sleep quality [ |